[HTML][HTML] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang… - Annals of …, 2019 - Elsevier
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
[引用][C] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang… - Annals of …, 2019 - cir.nii.ac.jp
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER
receptor tyrosine kinase inhibitor pyrotinib | CiNii Research CiNii 国立情報学研究所 学術情報 …
receptor tyrosine kinase inhibitor pyrotinib | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML][HTML] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang… - Annals of …, 2019 - annalsofoncology.org
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang… - Annals of oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang… - Annals of Oncology …, 2019 - europepmc.org
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang… - Annals of Oncology …, 2019 - europepmc.org
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …